Related Experiment Video
Updated: Mar 15, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Ginkgolide B-cyclodextrin inclusion complexes: an encapsulation strategy for improved solubility and aerosol
Yuying Wang1, MingLi Wei2, Yan Zhang3
1School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Abstract:
Bronchial asthma represents a long-term inflammatory reaction in the airways, marked by the accumulation of eosinophils. Ginkgolide B (GB), derived from ginkgo biloba, serves as a potent natural antagonist of platelet activating factor (PAF). It can greatly reduce the production and release of eosinophils while minimizing the infiltration of other inflammatory cells in the airways, thus contributing to the management of bronchial asthma. However, due to its low bioavailability caused by poor water solubility and inherent bitter taste, it's hard for Ginkgolide B to meet the standards required for effective treatment of asthma. In this study, we developed two cyclodextrin derivatives of Ginkgolide B, namely GB-SBE-β-CD and GB-HP-γ-CD, for the therapy of bronchial asthma through aerosol inhalation. Both SBE-β-CD and HP-γ-CD effectively capsulated the Ginkgolide B. Molecular docking analysis revealed the spatial structure of GB-SBE-β-CD and GB-HP-γ-CD, highlighting hydrogen bonding as the primary driving force behind their formation. In vitro cell assays demonstrated that both Ginkgolide B and Ginkgolide B-cyclodextrin inclusion compounds exhibited good safety and potent anti-inflammatory activity. In addition, inhalation of aerosolized GB-SBE-β-CD and GB-HP-γ-CD markedly alleviated the symptoms of OVA-induced asthma in BALB/c mice, lowering infiltration of inflammatory cells, and significantly contributing to asthma treatment. The current findings suggest that the inhalation of Ginkgolide B-cyclodextrin represents a safe and promising option for managing bronchial asthma.
Related Concept Videos
Inhaled Medications
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

